Kala Bio wins conditional Nasdaq listing extension for bid-price noncompliance
KALA•Nasdaq’s hearings panel conditionally extended Kala Bio’s listing on November 13, 2026. The company must close at or above $1 for 10 consecutive business days by November 30 and maintain that level through February 23, 2027.
1. Compliance conditions
Kala Bio must achieve a closing bid price of at least $1 for 10 consecutive business days by November 30, 2026, and keep its closing bid price at or above $1 each trading day through February 23, 2027. Any other listing violation before then would give the company seven days to submit a remediation plan; the panel could grant relief or delist the company. If Kala Bio remains compliant through February 23, the panel intends to impose a discretionary monitor for the following year.




